SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to its rapidly expanding ecosystem, evidenced by rising TVL, app revenue, and user growth, driven by its advanced ZK-STARK technology, increasing Bitcoin DeFi integrations, and ongoing focus on quantum resistance and privacy. The community widely discusses its robust long-term infrastructure build, viewing current valuations as a potential mispricing despite recent token unlock conversations.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a public stock offering and a substantial royalty funding agreement, which the community is debating as either a necessary strategic capital raise to advance its oncology pipeline and meet financial obligations, or as a significant, ill-timed dilution impacting short-term share value.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL (GRAL) is experiencing a sharp decline following mixed trial results for its Galleri cancer test in a UK study that missed a primary endpoint, with bears predicting further collapse. However, many in the community view this as an overreaction, citing strong underlying data for early cancer detection, substantial cash reserves, an ongoing US FDA submission, and recent institutional investments at higher valuations.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending after its Q4 earnings, which showed strong revenue growth but an EPS miss, as the company prioritizes significant investments in pipeline expansion, including a new patent extending protection to 2042 and dosing the first patient in a Phase 3 CIC trial. Investors are debating the short-term impact of increased expenses versus the long-term value from a potential buyout and rising analyst price targets, despite general market volatility.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending sharply lower following a reported Q4 loss and cautious Q1 forecast, largely impacted by increased credit loss provisions. The community is actively debating the long-term viability of its Buy Now, Pay Later model and its path to profitability, with some viewing the significant price drop as an overreaction.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is heavily discussed as it experiences significant price fluctuations, with the community divided on short-term outlooks while the ecosystem sees increasing institutional interest in staking loans and new privacy solutions like GhostwareOS, bolstering its push to scale traditional finance on-chain.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token ($VVV) is surging amid strong community sentiment around its unique private and uncensored AI platform, further fueled by significant token burns and an upcoming supply emission reduction. Increased platform utility and developer partnerships in the thriving AI crypto sector are driving widespread anticipation for continued upward momentum.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ, an inverse ETF to MicroStrategy, is seeing intense discussion following recent sharp declines that caused losses for many, yet a strong contingent of the community remains convinced an impending MSTR and Bitcoin downturn will drive MSTZ significantly higher.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris is trending as its competitor Corcept's recent FDA setback for relacorilant effectively clears the path for Xeris's rapidly growing Recorlev in the Cushing's market. Despite an initial market overreaction, the community is actively discussing this as a prime buying opportunity ahead of anticipated strong Q4 earnings and the progression of its promising XP-8121 pipeline.

Codatta

Codatta (XNY CRYPTO) is trending as it demonstrates significant strength and outperformance amidst broader market fluctuations, leading the community to aggressively buy dips and anticipate further upward movement. Discussions highlight its underlying utility in decentralized AI and data.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Braskem (OTCMKTS:BRKMY) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Braskem (OTCMKTS:BRKMY) Shares Pass Above 200-Day Moving Average - Should You Sell...

Braskem S.A. (NYSE:BAK) Sees Significant Growth in Short Interest

Braskem S.A. (NYSE:BAK - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 3,745,521 shares, an...

Braskem (NYSE:BAK) Shares Down 11.7% - Should You Sell?

Braskem (NYSE:BAK) Stock Price Down 11.7% - Here's What Happened...

Braskem (OTCMKTS:BRKMY) Stock Crosses Above Two Hundred Day Moving Average - Here's Why

Braskem (OTCMKTS:BRKMY) Shares Pass Above 200 Day Moving Average - What's Next...

Braskem S.A. (NYSE:BAK) Sees Large Decline in Short Interest

Braskem S.A. (NYSE:BAK - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 2,821,234 shares, a decrease of 15.0% from the...

Braskem (NYSE:BAK) Trading 8.4% Higher - Still a Buy?

Braskem (NYSE:BAK) Shares Up 8.4% - Still a Buy...

Braskem (NYSE:BAK) Downgraded to "Hold" Rating by Zacks Research

Zacks Research downgraded shares of Braskem from a "strong-buy" rating to a "hold" rating in a research report on Monday...

Braskem S.A. (NYSE:BAK) Short Interest Up 39.6% in December

Braskem S.A. (NYSE:BAK - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 3,320,975 shares, a growth of...

Braskem (OTCMKTS:BRKMY) Share Price Crosses Above 200-Day Moving Average - Here's What Happened

Braskem (OTCMKTS:BRKMY) Share Price Passes Above 200 Day Moving Average - Here's What Happened...

Braskem (NYSE:BAK) Shares Gap Down - Here's Why

Braskem (NYSE:BAK) Shares Gap Down - Should You Sell...

Braskem SA engages in the manufacture of petrochemicals and other related products. It operates through the following segments: Brazil, USA, and Europe and Mexico. The Brazil segment includes production and sale of chemicals, supply of electricity, and production and sale of PE. The USA and Europe segment involves production, operation, and sale of polypropylene in the United States and Germany. The Mexico segment comprises production, operation, and sale of ethylene, high-density polyethylene and low-density polyethylene in Mexico. The company was founded in August 2002 and is headquartered in Butanta, Brazil.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.99	--	--	N/A
Q3 '25	-$0.57	-$0.50	12.28%	BEAT
Q2 '25	-$0.60	-$0.15	74.53%	BEAT
Q1 '25	$0.48	--	--	N/A
Q4 '24	-$0.88	--	--	N/A

BAK
Braskem S.A.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BAK News

BAKBraskem S.A.